story of the week
Capivasertib + Fulvestrant Improves Activity and Tolerability in AKT1E17K-Mutant, ER+ MBC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer
Clin. Cancer Res 2020 Apr 20;[EPub Ahead of Print], LM Smyth, K Tamura, M Oliveira, EM Ciruelos, IA Mayer, MP Sablin, L Biganzoli, HJ Ambrose, J Ashton, A Barnicle, DD Cashell, C Corcoran, EC de Bruin, A Foxley, J Hauser, JPO Lindemann, R Maudsley, R McEwen, M Moschetta, M Pass, V Rowlands, G Schiavon, U Banerji, M Scaltriti, BS Taylor, S Chandarlapaty, J Baselga, DM HymanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.